Cover - USD ($) |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2025 |
Apr. 17, 2026 |
Jun. 30, 2025 |
|
| Cover [Abstract] | |||
| Document Type | 10-K/A | ||
| Amendment Flag | true | ||
| Amendment Description | Part III, Amendment 1 | ||
| Document Annual Report | true | ||
| Document Transition Report | false | ||
| Document Period End Date | Dec. 31, 2025 | ||
| Document Fiscal Period Focus | FY | ||
| Document Fiscal Year Focus | 2025 | ||
| Current Fiscal Year End Date | --12-31 | ||
| Entity File Number | 001-37937 | ||
| Entity Registrant Name | XENETIC BIOSCIENCES, INC. | ||
| Entity Central Index Key | 0001534525 | ||
| Entity Tax Identification Number | 45-2952962 | ||
| Entity Incorporation, State or Country Code | NV | ||
| Entity Address, Address Line One | 945 Concord Street | ||
| Entity Address, City or Town | Framingham | ||
| Entity Address, State or Province | MA | ||
| Entity Address, Postal Zip Code | 01701 | ||
| City Area Code | 781 | ||
| Local Phone Number | 778-7720 | ||
| Title of 12(b) Security | Common Stock, $0.001 par value per share | ||
| Trading Symbol | XBIO | ||
| Security Exchange Name | NASDAQ | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Voluntary Filers | No | ||
| Entity Current Reporting Status | Yes | ||
| Entity Interactive Data Current | Yes | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Small Business | true | ||
| Entity Emerging Growth Company | false | ||
| Entity Shell Company | false | ||
| Entity Public Float | $ 5,110,488 | ||
| Entity Common Stock, Shares Outstanding | 2,291,056 | ||
| ICFR Auditor Attestation Flag | false | ||
| Document Financial Statement Error Correction [Flag] | false | ||
| Insider Trading Policies and Procedures Adopted [Flag] | true | ||
| Award Timing MNPI Disclosure [Text Block] | We do not currently have any policies or procedures that require us to grant equity awards, including stock options, to executive officers on specified dates. Equity awards to executive officers are granted at such times as determined in the discretion of the Compensation Committee. Neither the Compensation Committee nor the Board of Directors takes material nonpublic information into account when determining the timing and terms of equity awards, including stock options, and we do not time the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation. During 2025, we did not grant any equity awards to any of our NEOs within four business days prior to or one business day after making any filing on Forms 10-K, 10-Q or 8-K (other than a current report on Form 8-K disclosing a new material option award grant under Item 5.02(e) of that form) that disclosed any material non-public information. | ||
| Award Timing MNPI Considered [Flag] | false |